NYSE · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Actinium Pharmaceuticals, Inc. ATNM
19 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 90,000.00
Revenue, FY2025 · full 19-year series below
Revenue $M
Net income $M
FY2025 · Revenue 0.1 · Net income -33.9
Compound annual growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−37652 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -40274.4% · Net -37652.2%
ROE
FY2025 · ROE -167.0%
Each USD of equity lost 167 cents this year.
The 19-year record
19 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | · | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 | · | · | · |
| Operating income $B | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · |
| EBITDA $B | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · | · |
| Income tax $B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.0 | −0.0 | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · | · | · |
| EPS, diluted $ | −1.09 | −1.27 | −1.83 | −1.37 | −1.20 | −1.83 | −4.40 | −0.22 | −0.40 | −0.50 | −0.55 | −0.90 | −0.47 | −7.58 | −4.30 | 0.01 | · | · | · |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −167.0 | −110.6 | −94.9 | −47.2 | −36.7 | −66.4 | −303.0 | −210.4 | −167.9 | −121.7 | −209.7 | · | · | −782.3 | −495.3 | −75.1 | −136.9 | −146.2 | −162.4 |
| Shares out B | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.01 | 0.12 | 0.08 | 0.06 | 0.04 | 0.03 | 0.02 | 0.02 | 0.01 | 0.01 | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 68 reconciliationsAUDITED
Reconciled in 19 of 19 fiscal years. 26 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2007